

[185] REINVENTING PREGNANCY MONITORING AND MANAGEMENT FOR THE 21ST CENTURY

Noah Klein, Director of Corporate Strategy & Business Development

Investment Rational

Nuvo develops a connected monitoring and management platform between obstetricians and pregnant women. Nuvo solves for data access, by shifting delivery of care out of the clinic and into the home. Nuvo's world-class BoD and Advisory Board includes the leading business and medical minds, including Prof. Varda Shalev, Deb Henretta, and Prof. Larry Platt.

Business Strategy

Nuvo is targeting the US as its lead market, but is pursuing key strategic ex-US initiatives, including with the Denmark Ministry of Health and Maccabi Healthcare. Near-term customers are the Providers, delivering value in the form of reduced administrative expenses, and increased compliance and patient convenience. With Big Data, Nuvo will turn to the Payor as its customer by reducing bad outcomes, e.g. predicting and reducing the risk of pre-term birth.

Core Technology

Invu captures high-fidelity raw data from mom and baby via a self-administered wearable sensor band, transmits to the cloud where advanced digital signal processing filters the data into actionable outputs, and visualizes data through unique interfaces for every stakeholder. Invu is the only home-use, accurate, and safe methodology of capturing medical-grade data of both mom and baby.

Product Profile/Pipeline

Invu has completed a global, multi-site pivotal and usability study, and has submitted to the FDA as a Class II DeNovo. Nuvo is selecting a Pilot site for the US, preparing for a Pilot with Maccabi, and is leading the process for a national bid in Denmark. Nuvo has secured a grant from J&J, in collaboration with Columbia University, to identify the biomarker for maternal mood disorder and its adverse effect on fetal wellbeing.

What's Next?

Nuvo has started its second multi-site pivotal study to validate a scientific breakthrough in capturing uterine activity, additional technologies are being integrated to its platform, and new biomarkers are being validated, including a uterus pacemaker and maternal and fetal arrhythmia detection. Nuvo has raised \$35MM+ to date and is expecting to raise a large financing round by 4Q19.